Scancell Holdings (FRA:SCP) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SCP Scancell Holdings PLC FRA:SCP
23 GF Score
Price €0.18
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:SCP
23GF Score
Scancell Holdings PLC FRA:SCP
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Business Description

Other Exchanges SCNLF:USASCLP:UK
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
23GF Score

Get the complete analysis for FRA:SCP

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price